To evaluate the effect of simultaneous administration of vitamin A and
Oral Polio Vaccine (OPV) on seroconversion to OPV a randomized double
-blind, placebo-controlled trial was conducted. Fifty-seven infants we
re randomly given either 50,000 I.U. vitamin A (n=34) or placebo (n=23
) with each OPV vaccine at monthly intervals. Seroconversion to polio
were 81% (79% in vitamin A group and 83% in placebo group, p=0.76) for
polio virus type 1, 86% (82% in vitamin A group and 91% in placebo gr
oup, p=0.34) for polio virus type 2, and 84% (82% in vitamin A group a
nd 87% in placebo group, p=0.64) for polio virus type 3. A multiple lo
gistic regression model was done to examine the factors associated wit
h reduced seroconversion (polio virus type 1). For adequate vitamin A
status the adjusted odds ratio of seroconversion was 0.24 (95 % CI: 0.
04-1.49, p=0.11) and that for high maternal antibody was 0.II (95 % CI
: 0.02-0.68, p=0.015). The geometric mean titer (GMT) was significantl
y lower in infants with adequate vitamin A stores compared to vitamin
A deficient infants (p=0.04; Mann-Whitney test). The results of this s
tudy suggest that vitamin A supplementation had no effect on seroconve
rsion, however, in children with adequate Vitamin A status there was a
trend towards lower seroconversion. High maternal antibody was signif
icantly associated with reduced seroconversion to the oral polio vacci
ne. (C) 1998 Elsevier Science Inc.